Trabajo de Investigacionqqq

7/26/2019 Trabajo de Investigacionqqq

1/35

MINISTERIO DE SALUD Y DEPORTESGOBERNACION DEL DEPARTAMENTO DE ORURO

SERVICIO DEPARTAMENTAL DE SALUDUNIVERSIDAD TECNICA DE ORUROFACULTAD DE CIENCIAS DE SALUD

CARRERA DE MEDICINA

INFORME TRIMESTRAL

SERVICIO SOCIAL DE SALUD RURAL OBLIGATORIO

PREVALENCIA DE LOS FACTORES DE RIESGO PARA LASENFERMEDADES NO TRANSMISIBLES EN EL CANTON DE

OPOQUERI EN EL PRIMER TRIMESTRE DE LA GESTION2015

RED DE SALUD : CUENCA POOPO

CENTRO DE SALUD : CENTRO DE SALUD OPOQUERI

NOMBRE Y APELLIDO : PAOLA CAMILA QUISPE MAMANI

FECHA DE ROTACION : 01 DE ENERO AL 30 DE MARZO DE2015

DOCENTE ASISTENCIAL : DRA. CINTHIA LLAVE GARCIA

NOMBRE DEL COORDINADOR SSSRO : DR. TAPIA

1


2/35

Mi i!"#$% &'$&(#"i)i#!*% & +& D$&. Ci!*,i&-%$ /&+i%& #!#&!& "%!"#%4 &*&)6i7! & +& E!8. A9i+i&$ Ai(& Vi(&+ -%$ #!#&!& &-%% #! +& $#"%+#""i! (# +%(&*% -&$& #+ -$##!*# *$&6&%.

A )i -&($# ;# i! #++% !% #$& +% ># &,%$& %4># Di% )# +% 6#!(i'&4 '$&"i& -%$ *%(& +*#$!i(&(.

2


3/35

A. PRIMERA PARTE: INFORME DE LA ROTACION1. RESUMEN EJECUTIVO

D$&!*# #+ *i#)-% (# $%*&"i! (# +% )## (# E!#$%4 F#6$#$% M&$% # */% !*$&6&% #-#"i&+ (# +& &*#!"i! M#(i"& ># # $#&+i& (# )&!#$& (i&$i& "%! +& &6#$*$& (# -#$*& (#+ C#!*$% (# S&+( (# O-%>#$i #! ,%$&$i% (# 0?:00 & 12:00 1@:00 &

1:004 # &*#!(i (# 8%$)& $#'+&$ "%!+*%$i% #9*#$!% i#)-$# >#(!(%# #+ M7(i"%i#$ #)#$'#!"i& & #& ($&!*# +&,%$& (# +& !%",# % +& M&($'&(& &"(i#!(% (# 8%$)& i!)#(i&*&4 C%!*&!(% "%! *$#)#(i% (# *$&!-%$*#4 U!& A)6+&!"i&4 )&!#&(& -%$ ",%8#$ & (i-%i"i! (#"&+>i#$ ++&)&(% (# #)#$'#!"i& #! $#& (# i!8+#!"i& (#+ C#!*$% (# S&+( "%)%%! +& C%)!i(&(# (# S&! # i$/# (# *$&!-%$*# -&$& /ii*& (%)i"i+i&$i&"#$"&!& & +& -%6+&"i!.

E! C&!*% & +& /&"!&4 "$#"i)i#!*% (#&$$%++% 8&$)&"i& # )&!#&(% ) -%$ #+-#$%!&+ (# #!8#$)#$& "%)% #+ Li"#!"i&(% +& E!8#$)#$& A9i+i&$4 *#!i#!(% !& 6#!&"%6#$*$&.

E! +% $#8#$#!*# &+ *$&6&% (#+ I!*#$!% (# M#(i"i!& #*/% i#)-$# "%)% &-%% &+ -#$%!&+M7(i"%4 "%! ) i!*#$7 #! #+ *$&6&% "%! +& "%)!i(&( & #& "%! ",&$+& #! S&+((i$i'i(% & i!*i*"i%!# "%)% C%+#'i% #"#+& (# +& C%)!i(&(# (# O-%>#$i4 S&!#$i "%)% #! +% &+#(&%4 #!"#*&!(% #/&+&!(%"+!i"&)#!*# %6$# +% F&"*%$# (# Ri#'% -&$& +& E!8#$)#(&(# N% T$&!)ii6+#4 #!(%!(# # i!"+ & *%(& +& P%6+&"i! *&!*% R#i(#!*# ># ++#'&$%! -&$& A"*i/i(&(#S%"i&+# "%)% #+ D&&$ C&$!&/&+#.

3


4/35

2. INFORMACION GENERAL DEL SISTEMA DE SALUD2.1 DATOS GENERALES DEL SISTEMA DE SALUD A NIVEL NACIONAL

2.1.1. Organ!a"#n G$n$ra% &$% S'($)a &$ Sa%*&

2.1.2. D$'"r+",n &$ %a R$&$' &$ 'a%*&

2.2. ORGANI-ACIN DEL CENTRO DE SALUD U /OSPITAL DONDE REALI-OSU ROTACION

2.2.1 Oragan!a",n &$ %a E'(r*"(*ra G$n$ra% &$ '$r", &$ 'a%*&

4

SEDES

RED CUENCA

REA COR UE

CENTRO DE SALUD

MINISTERIO DE SALUD Y

GOBERNACIN DEL DEPARTAMENTO

SEDES ORURO

RED CUENCA

PUESTOS DEREA COR UE

SAN OS DE

CENTRO DE SALUD

SAN


5/35

INGRESO DEL PACIENTE

VACUNACRECIMIENTODESARROLLO

ENFERMERIACURACION

SUTURAS, SUEROSCIRUGIA MENOR

ODONTOLOGIA

CONSULTORIO EXTERNO CLINICODIAGNOSTICOTRATAMIENTO

REFERENCIAORIENTACION

ENFERMERIAADMISIONFILIACION

SIGNOS VITALESINFORMACIONORIENTACION

PLANIFICACION FAMILIARORIENTACION

SALUD REPRODUCTIVATOMAS DEL PAP

DOTSTBBACILOSCOPIA

FARMACIA

EGRESO DEL PACIENT

2.2.2 Organgra)a &$ %a r$& *"a"#n &$% S$r", &$ Sa%*&

SEDES ORURO: D$.GERENCIA DE RED CUENCA POOPO: D$.

CENTRO DE SALUD CORQUE: D$&. Vi"*%$ L#(#)&CENTRO DE SALUD OPOQUERI:MEDICO: D$. Ci!*,i& L+&/# G&$"i&ODONTOLOGA: D$. D#+i!& M%!*%& G%!&+#LIC. ENFERMERIA: Li". S#+i!' C&)-% T&-i&

AUILIAR DE ENFERMERJA: E!8: A(& Vi(&+ H#$$#$&INTERNO DE MEDICINA: P&%+& C&)i+& Qi-# M&)&!iINTERNO DE LIC. ENF.: P&)#+& A$i& C,%>#"&++&*&INTERNA DE AU. ENF.: M%!i"& . C%+># M&)&!i Li(i& A!"&i C%+>#

CONDUCTOR DE AMBULANCIA: S#$&8i! R%($i'#2.2.3 F+%'$&)& (# &*#!"i!

!

ENFERMEFARMACODONTOLOMEDICI


6/35

2.2.3 A($n",n$' '$r",' 4*$ +r$'(a a %a +,%a"#n

E+ C#!*$% (# &+( (# O-%>#$i "#!*& "%! #>i-&)i#!*% -#$%!&+ (# S&+( -&$&-$#*&$ +% i'i#!*# #$/i"i%:

A*#!"i! M7(i"&. ;#$/i"i% (# "%!+*%$i% #9*#$!% #)#$'#!"i&=

A*#!"i! O(%!*%+'i"&.

A*#!"i! (# #!8#$)#$& ; C$#"i)i#!*% (#&$$%++%4 V&"!&"i!=

S#$/i"i% (# A)6+&!"i&.

2.2.5 D$'"r+"#n &$ %a Inra$'(r*"(*ra

E+ C#!*$% (# S&+( O-%>#$i "#!*& "%! +% i'i#!*# &)6i#!*#:

C%!+*%$i% M7(i"%. C%!+*%$i% O(%!*%+'i"%.

C$#"i)i#!*% (#&$$%++%.

A)6i#!*# (# /&"!&"i!.

S&+& (# -&$*% -%-&$*%

F&$)&"i&.

S&+& (# #-#$&.

C%"i!&.

@ &)6i#!*# "%)% (%$)i*%$i% (#+ -#$%!&+ (# &+(.

2.2.6 E4*+a)$n(,

E+ C#!*$% (# S&+( O-%>#$i # #!"#!*$& #>i-&(% "%! )&*#$i&+ -&$& +& &*#!"i!M#(i"& #! "%!+*%$i% #9*#$!%4 A*#!"i! P#(i*$i"&4 )#& (# "$&"i%!# "%! *%(% #+#>i-&)i#!*%4 )&*#$i&+ -&$& $#&+i&$ "%!*$%+# -$#!&*&+#4 &(#) (# )&*#$i&+ -&$&&*#!"i! (# -&$*% (%)i"i+i&$i% (# #)#$'#!"i&4 "#!*& "%! )&*#$i&+ -&$& +& &*#!"i! (#C$#"i)i#!*% (#&$$%++%4 )&*#$i&+ (# /&"!&"i! $#-#"*i/% $&*$i++.C#!*& "%! ! "%!+*%$i% O(%!*%+'i"% "%! $#-#"*i/& i++& %(%!*%+'i"&4$&(i%'$&8i& *%(% #+ )&*#$i&+ -&$& $#&+i&$ +& &*#!"i! !#"#&$i&.

A(#) "#!*& "%! *$# )#(i% (# *$&!-%$*#4 !& A)6+&!"i&4 !& M%*% !&6i"i"+#*&4 P&$& &"(i$ ,& ++&)&(% & +& (i8#$#!*# E)#$'#!"i&.

"


7/35

2.2.7 A+,, Dagn,'(",

E+ C#!*$% (# S&+( O-%>#$i %+% "#!*& "%)% &-%% (i&'!%*i"% T#!i)#*$% *&!*%(i'i*&+ "%)% $%6i%4 F%!#!(%"%-i% *&!*% -&$& &(+*% "%)% -#(i*$i"%4 %9i)#*$% (#-+%4 +i!*#$!&4 O*%"%-i%4 D%)-+#$.

2.2.8 R$"*r',' /*)an,'

E+ C#!*$% (# S&+( O-%>#$i "#!*& "%! #+ i'i#!*# -#$%!&+:

PERSONAL DE PLANTA:

o MEDICO : D$. Ci!*,i& L+&/# G&$"i&

o LICENCIADO EN ENFERMERIA: Li". S#+i!' C&)-% T&-i&

o AUILIAR DE ENFERMERIA: E!8: A(& Vi(&+ H#$$#$&

o MEDICO ODONTOLOGA: D#+i!& M%!*%& G%!&+#

o CHOFER DE AMBULANCIA: S#$&8i! R%($i'#

o INTERNOS:

INT.K MEDICINA: P&%+& C&)i+& Qi-# M&)&!i

#"&++&*&

INT.K AU. ENFERMERIA: Li(i& A!"&i C%+>#

M%!i"& i)#!& C%+># M&)&!i

9. ACTIVIDADES

9.1. ACTIVIDADES DE CONSULTA ETERNA

9.1.1. C,)+r$n&$ (a);n %a' a"(&a&$' &$ $)$rg$n"a'P&"i#!*# &*#!(i(% #! "%!+*& #9*#$!& #)#$'#!"i& -%$ #(&( #9%:

#


8/35

MES DE ENERO

$


9/35

C%)-$#!(# *&)6i7! +& &"*i/i(&(# (# #)#$'#!"i&.

%


10/35

MES DE FEBRERO

1&


11/35

C%)-$#!(# *&)6i7! +& &"*i/i(&(# (# #)#$'#!"i&.MES DE MARZO

S# $#&+i&! +& i'i#!*# &"*i/i(&(# &"(i#!(% & #*& #)#$'#!"i& #! +& )&%$&(# +% "&% "%! $#8#$#!"i& & +& "i(&( (# O$$%.

E!*$# +& +r)$ra' 10 "a*'a' &$ ",n'*%(a $


12/35

. C#8&+#&.

. S!($%)# &+7$'i"% -%$ -i"&($& (# i!#"*% %*$%

?. E*$#i)i#!*% "%!*i-&"i!

10.I)-7*i'% K -i% (#$)i*i

9.2. ACTIVIDADES /OSPITALARIAS

9.2.1 Pa"$n($' /,'+(a%!a&,' a($n&&,' +,r $&a& '$$r$'

1. NEUMONJAS

2. ACCIDENTES

3. EDAS

@. SJNDROME ALRGICO POR PICADURAS DE INSECTOS.

5. ABDOMEN AGUDO.

E! )&%$# (# "i!"% &%

1. NEUMONJAS

2. ACCIDENTES

3. ABDOMEN AGUDO@. EDAS

5. SJNDROME ALRGICO POR PICADURAS DE INSECTOS.

9.2.9. T*rn,' $n $% "$n(r,

S# $#&+i *$!% (# )&!#$& -#$)&!#!*# #! #+ C#!*$% (# S&+(4 &"(i#!(% &+++&)&(% (# "&+>i#$ #)#$'#!"i&.

9.2.3. Tran'$r$n"a a ,(r,' '$r",' &$ 'a%*& ",n n,(a &$ r$$r$n"a

0?K01K15 O-%>#$i O$$% T$&!8#$#!"i& -%$ F$&"*$& (# C%++# & +& S$&. M&$i&Qi-# C,%>#

21K02K15 O-%>#$i O$$% T$&!8#$#!"i& -%$ F$&"*$& (# C%++# &+ Ni%


13/35

9.9. ACTIVIDADES MATERNO INFANTIL

9.9.1. C,n'*%(a Ei",i$i

o V#$i!& H&$&",i

o A6i'&i+

o E(i*, Z+#)& B#!&/i(# G&$"i&

C,n(r,% N=, En$r),

o L% "%!*$%+# (# !i% #!8#$)% # $#&+i&$%! (# )&!#$& $#'+&$ "%!&i*#!"i& (# +& -%6+&"i! &+ C#!*$% (# &+( "&!(% !i% ##!8#$)& "%! !& -$#(%)i!&!"i& (# IRAS #'i(% (# Si!($%)&&+7$'i"% EDAS.

C,n(r,% N=, San,

o L% "%!*$%+# (# !i% &!% # $#&+i&! (# )&!#$& $#'+&$ )&!#&(& #! )&%$& -%$ #+ -#$%!&+ (# #!8#$)#$& "%! !& "%6#$*$& (#+ 100

"%! "%!*$%+# )#!&+# & )#!%$# (# 2 &% &(#) "%! +&&+i)#!*&"i! -+#)#!*&$i& & !i% )&%$# (# )## ,&*& +% (%&%4 C%! +& %$i#!*&"i! & +& )&($# ># # $#&+i& ++#!&!(% +& ,%& (#

AIEPI.

E&*"a"#n &$ %a Ma&r$

o D$&!*# "&(& "%!*$%+ (# !i% &!% &+ ++#!&(% (# +& ,%& (# AIEPI #$#&+i& !& %$i#!*&"i! & +& )&($# i! #9"#-"i! &+'!& %6$# +&&+i)#!*&"i! (#+ 6#6#4 #+ )&!#% (# +& &+i)#!*&"i! -+#)#!*&$i&-&$& !& )#%$ *%+#$&!"i& -%$ -&$*# (# 6#6#4 *&)6i7! ($&!*# +&

"%!+*& )7(i"& (# !i% #!8#$)% # %$i#!*& & +& )&($# %6$# +&!*$i"i! (#+ 6#6# ($&!*# #+ *$&!"$% (# $#*&6+#"i)i#!*%.

P%an"a"#n a)%ar: M&!#% (# I!)% C%!##$&

9.9.2. Sa%a &$ +ar(,'

E+ "#!*$% (# S&+( %-%>#$i "#!*& "%! !& &+& (# -&$*% (# i!*#$!&"i%!4 -#$% +&)&%$i& (# +% -&$*% &*#!(i(% ,&! i(% (%)i"i+i&$i% ,& ++&)&(% (# +& -&"i#!*# %

13


14/35

8&)i+i&$#4 &"(i#!(% *&)6i#! & (i8#$#!*# "%)!i(&(# #*&!"i& "%)%#)#$'#!"i& "%! &)6+&"i&4 $#&+i&!(% *&)6i#! $#8#$#!"i& i #+ "&% +% $#>i#$# ,&*+ H%-i*&+ (# C%$># (%!(# "#!*& *&)6i#! "%! &+& (# -&$*% (# i!*#$!&"i%! (#! )#(i"% #-#"i&+i*&4 (# i'&+ )&!#$& $#&+i&!(% *$#!8#$#!"i& ,&*'& +%,%-i*&+# (# 2(% 3#$ !i/#+ (# O$$%.

9.9.9. Traa>, &$ +ar(,

E! +& "%)!i(&( (# O-%>#$i (#6i(% & +& *$&(i"i%!# (# +& -%6+&"i! *%(% #+*$&!"$% (#+ *$&6&% (# -&$*% +& '#*&!*# #* #! (%)i"i+i% (%!(# #+ -#$%!&+ (#&+( &"(# ,& ++&)&(% "%! -%*#$i%$ )&!#% (#+ *$&6&% (# -&$*% -&$*% "%! +&)&%$ -i& -%i6+#.

9.9.3. A($n"#n &$ +ar(, +,r In($rn, A''(&, +,r M$&", D,"$n($

S$&. L" T&>i",i$i P&$*% E*"i"% D%)i"i+i&$i% RN: /i/% S#%: M&"+i!% P#%: 3?00T&++&: 52

S$&. V#$i!& H&$&",i Ni!& P&$*% E*"i"% D%)i"i+i&$i% RN: /i/% S#%: F#)#!i!%P#%: 3100 T&++&: 50

9.9.5. Sa%a &$ /,'+(a%!a",n$': C,n&*"(a r$n($ a% n=, %a )a&r$

E+ *$&!"$% (# -#$-#$i% i!)#(i&*% )#(i&*% #! -#$%!&+ (# &+( (#+ C#!*$% (#S&+( O-%>#$i +% )&!#& #! #+ (%)i"i+i% (# +& -&"i#!*# "%! /ii*& (i&$i& *&!*% & +&)&($# "%)% &+ $#"i7! !&"i(%.

9.9.6. A"(*a%!a"#n Ma($rn, Inan(%: n?)$r, &$ ($)a' &$ +r$'$n(a"#n &'"*'#n &$'arr,%%a&,' ",n $% +$r',na% &$ '$r", &$ 'a%*& $n r$%a"#n a %aSa%*& Ma($rn, Inan(%

EN FECHA 1 DE MARZO EL PERSONAL DE SALUD DEL C#!*$% (# S&+(O-%>#$i $#&+i% ! "$% #! #+ &(i*$i) (#+ C#!*$% %6$# +% i'i#!*# *#)&(i$i'i(% & )&($# (# 8&)i+i& *#!i#!(% 6#!& &i*#!"i& &(#) "%! $#-&$*i"i! (#$#8$i'#$i%.

K TALLER (# ANTICONCEPCIN A MADRES Y PADRES DE OPOQUERI

K TALLER SALUD ORALK SIGNOS DE PELIGRO EN MADRES GESTANTES Y EN NIOS MENORESDE 5 AOS

K ENFERMEDADES TRANSMISIBLES

K PAP

14


15/35

K CANCER CERVICOUTERINO

9.3. ENFERMEDADES TRANSMISIBLES

9.3.1. In)*n!a",n$': n?)$r, &$ a"(&a&$' r$a%!a&a'@ "a)+a=a' r$a%!a&a'

L& i!)!i&"i%!# # ++#/&! & "&6% #! #+ "#!*$% (# S&+( O-%>#$i )&!#&(& )-%$ #+ -#$%!&+ (# #!8#$)#$& *#!i#!(% !& "%6#$*$& (#+ ?? & (#) -#>i& $&*$i++ !& & (% /#"# &+ )#.

9.3.2. Dagn,'(", (ra(a)$n(, &$ "a','.

N% # (i&'!%*i"&$%! #! !i% )#!%$# (# 5 &% "&% (# T6#$"+%i4 Di8*#$i&4T#*&!%4 S&$&)-i%!4 R6#%+&4 #*".

9.3.9. P$'4*'a &$ C,n(a"(,'.

S# $#"%!%"i & -#$$% ># )%$(i#$%! & &+'!% &(+*%4 *#!i#!(% #'$i(&( (# +&/&"!&"i! (# +& )&"%*& &(#) (# #!/i (#+ -&"i#!*# & +& !i(&( (#E-i(#)i%+%'i& -&$& $#-#"*i/& /&"!&"i!.

9.3.3. Vg%an"a E+&$),%#g"a.

S# $#-%$*&! & +& !i(&( (# E-i(#)i%+%'i& #+ $#'i*$% #)&!&+ (%!(# # #!/& +%(&*% (# IRAS i! N#)%!& EDA.

9.5. GESTION SANITARIA

9.5.1 S'($)a &$ In,r)a"#n

9.5.2. S*''($)a &$ In,r)a"#n

9.5.9. S'($)a A&)n'(ra(,

L& -&$*# &()i!i*$&*i/& #*& )&!#&(& -%$ #+ )7(i"% (# -+&!*& #+ +i"#!"i&(% (#-+&!*& -%$ "&$#"#$ (# -#$%!&+ &()i!i*$&*i/%.

9.5.3. C,,r&na"#n ",n ,(ra' ,rgan!a",n$' $ n'((*",n$' 4*$ (raa>a $n'a%*&

E! #+ (#&$$%++% (# +& &"*i/i(&(# "%! +& "%)!i(&( # "%%$(i!&$%! "%! i!*i*"i%!#># *$&6&&! "%! S&+( "%)%:

FTO S&+( APROSAR D$&: E(i*, M%+% M&",&"&.

BONO


16/35

NUTRICIONISTA DIETISTA Li". M&$*& A+i"i& Qi-#.

9.5.5 C,,r&na"#n ",n )*n"+,' ,(ra' ,rgan!a",n$'

9.6. EDUCACION SANITARIA

9.6.1. E&*"a"#n n&&*a% $n ",n'*%(a /,'+(a%!a"#n a% +a"$n($ '*a)%a.

E! #+ *$&!"$% (# +& "%!+*& M7(i"& # -$%"#(# & +& #("&"i! (# 6#!% ,6i*%(# /i(& # ,i'i#!#4 -#$% *%)&!(% "%)% -$i%$i(&( "%!##$& %6$# #+ % (#MTODOS ANTICONCEPTIVOS Y PLANIFICACIN FAMILIAR4 FACTORES DERIESGO PARA LAS ENFERMEDADES NO TRANSMISIBLES4 #! (%!(# #/&+& & +&-#$%!& "%! 8&*%$# (# $i#'%.

9.6.2 E&*"a"#n ",n ($)a' &$ Sa%*& $n E'"*$%a'@ C,%$g,'.

K 10K02K15 C,&$+& #! S&+( Hi'i#!# P#$%!&+ C#-i++&(% "%$$#"*% (# (i#!*# "%!$#-&$*i"i! # "#-i++% -&*& (#!*&+# #! +& U!i(&( E("&*i/& R&8+ P&/%! (# +&C%)!i(&( (# S&! #$i.

K 2K02K15 C,&$+& #! S&+( ALCOHOLISMO Y EMBARAZO EN EDOLESCENTES#! #+ "%+#'i% #"!(&$i& (# +& "%)!i(&( (# O-%>#$i.

9.6.9. E&*"a"#n a gr*+,' ,rgan!a&,'@ ",), 'n&"a(,'@ gr*+,' &$ )a&r$' *,(ra' ,rgan!a",n$' n&"an&, n?)$r, ($)a'

K01K03K15 C,&$+& #! S&+( FACTORES DE RIESGO PARA LAS ENFERMEDADESNO TRANSMISIBLES #! +& C%)!i(&( (# P%)&*&

K 05K03K15 C,&$+& #! &+( FACTORES DE RIESGO PARA LAS ENFERMEDADESNO TRANSMISIBLES #! +& "%)!i(&( (# S&! "$i*%6&+.

K 0K03K15 C,&$+& #! &+( ENFERMEDADES CRONICAS NO TRANSMISIBLES

#! +& C%)!i(&( (# P%)&*&.

9.6.3. E&*"a"#n a (ra;' &$ )$&,' &$ ",)*n"a"#n: Ra&, ($%$'#n.

S# ++#/% #("&"i! #! &+( & *$&/7 (#+ $#-&$*% (# T$-*i"% %6$# #&+# (# -#+i'$%#! #)6&$&&(&4 %6$# #+ VIH SIDA4 T6#$"+%i.

1"


17/35

3 OTRAS ACTIVIDADES REALI-ADAS

3.1. Dagn,'(",' Ra+&,'

3.2 O(ra' n$'(ga",n$'.

S# ++#/ & "&6% +& i'i#!*# i!/#*i'&"i!:

PREVALENCIA DE LOS FACTORES DE RIESGO PARA LAS ENFERMEDADES NOTRANSMISIBLES EN EL CANTON DE OPOQUERI EN EL PRIMER TRIMESTRE DELA GESTION 2015

5 ANALISIS DE LA ROTACION

5.1. C*)+%)$n(, &$ A"(&a&$'

L& &"*i/i(&(# (# C%!+*%$i% &*#!"i! )#(i"& #! "%)!i(&(# &(#) (#*$&6&% "%! +& "%)!i(&( # D#&$$%++&$%! "%! "%)-+#*& N%$)&+i(&(.

5.2. A+,, &,"$n($ 4*$ r$"# +,r %,' );&",' ,(r,' +r,$',na%$'

C%)% i!*#$!& (# +& "&$$#$& (# M#(i"i!& E*/# 6&% +& T*%$& (# +& D$&. Ci!*,i&L+&/# G&$"i& #/ii*&! (# )&!#$& $#"$$#!*# #+ C#!*$% (# S&+( "%)%:

FTO S&+( APROSAR D$&: E(i*, M%+% M&",&"&.

5.9. S(*a",n$' &$ ",n%"(, +r$'$n(a&a' %a ,r)a 4*$ *$r,n+%an($a&a' r$'*$%(a'

D$&!*# #+ (#&$$%++% (# +& &*#!"i! M7(i"& #! #+ C#!*$% (# S&+( O-%>#$i #!&+'!& %"&i! # */% (i8i"+*&( (#6i(% &+ +i)i*&(% -#$%!&+ (#+ C#!*$% (# S&+(

D#6i(% & ># #! %"&i%!# # -$##!*&$%! (% i*&"i%!# (# #)#$'#!"i& (#8%$)& i)+*!#& (%!(# # */% ># ,&"#$ #+ % *&!*% (# +& &)6+&!"i& +&)%*%"i"+#*& "%! $#-&$*i"i! (#+ -#$%!&+ (# &"#$(% & +& (i-%i"i!.

6 SUGERENCIAS

6.1 Para %,grar "a),' +,'(,' $n $% S$r", &$ 'a%*&

K P#$%!&+ (# S&+( "%! ) "&-&"i*&"i! (#i'!&(& & *$&/7 (# #9)#!# (# 8%$)&*$&!-&$#!*#.

1#


18/35

K Di)i!i$ +& 6$%"$&"i& #! #+ -#$%!&+ (# &+( & ># $#*&! #+ *i#)-% ># #-%($& (#*i!&$ &+ *$&6&% (i$#"*% "%! +& "%)!i(&(.

6.2 Para )$>,rar $n *n",na)$n(, &$ %,' +r,gra)a' &$ 'a%*&

P&$& ! (#&$$%++% (# +% -$%'$&)& (# &+( -i#!% ># # ++#/&$& & "&6% "%! !&)#%$ "%6#$*$& i #+ -#$%!&+ (# &+( *i#!# "%!%"i)i#!*% % #*7 -+#!&)#!*#"&-&"i*&(%.

6.9 Para )$>,rar %a r,(a"#n &$ SSSRO

B$i!(&$ & +% I!*#$!% (# M#(i"i!& )#%$# "%!(i"i%!# ) "%)%(i(&( -&$& >#+& #!#$'& (##)-#% #&! (i$i'i(& &+ (##!/%+/i)i#!*% & #& #! +& &*#!"i!)#(i"& % *$&6&% "%! +& "%)!i(&(.

7 ACREDITACION

1$


19/35

1 RESUMEN EJECUTIVO

E+ i'i#!*# *$&6&% # $#&+i "%! #+ -$%-i*% (# "%!%"#$ +% $#8#$#!*# & +& -%6+&"i!(# O-%>#$i %6$# +% F&"*%$# (# Ri#'% -&$& +& E!8#$)#(&(# !% T$&!)ii6+#4*#!i#!(% "%)% ! !i"% %6#*i/% '#!#$&+: "%!%"i)i#!*% (# +& -$#/&+#!"i& (# +%8&"*%$# (# $i#'% -&$& +& #!8#$)#(&(# !% *$&)ii6+# ,&"#$ #+ (i&'!%*i"% (#Di&6#*#4 Hi-#$*#!i! A$*#$i&+4 O6#i(&(4 (&$ & "%!%"# & +& -%6+&"i! & "#$"& (#+& -$#/#!"i! "%!*$%+ (# +& #!8#$)#(&(# !% *$&)ii6+#. R#&+i!(%# ! *i-% (##*(i%: "&!*i*&*i/%4 (#"$i-*i/%4 *$&!/#$&+. C%! !i(&(# (# %6#$/&"i!. S# ,&"#! #*(i% #! +& "%)!i(&( (# O-%>#$i *$&6&&!(% "%! *%(& +& -#$%!& #! #(&((# $i#'% *&!*% ,%)6$# "%)% )#$#. A(#) (# ! !i/#$% (# #*(i%. T%)&!(%

& 0 -#$%!& (# +& "%)!i(&( (# O-%>#$i (# #9% )&"+i!% 8#)#!i!%.M#*$&. 100 -#$%!& (# +& "%)!i(&( (# O-%>#$i (# #9% )&"+i!% 8#)#!i!%#! #(&( (# $i#'%. E"%'i#!(% +& )#*$& (# 8%$)& &+#&*%$i& i)-+#. Si!*#*i&(& #!-#$%!& ># &"(#! & +& "%!+*& )7(i"& #*$&*i8i"&(& & -#$%!& >#"%)-$#!(#! #!*$# +% 25 & 0 )&%$# & 0 &%. T%)&!(% #! "#!*& "$i*#$i%. D#i!"+i!: 100 -#$%!& ># $#i(#! #! +& "%)!i(&( (# O-%>#$i (# #9% )&"+i!% 8#)#!i!% ># "%)-$#!(#! #!*$# +% 25 0 )&%$# & 0 &%. Y "$i*#$i% (##9"+i!: & -#$%!& ># !% #*7! #! +& #(&(# i!(i"&(&4 ># !% "%$$#-%!(&!& +& "%)!i(&( (# O-%>#$i. S# *i+i& "%)% 8#!*# (# i!8%$)&"i!. E!*$#/i*& (#8%$)& (i$#"*& )#(i&!*# ! i!*$)#!*% (# $#"%+#""i! (# (&*% & +& -%6+&"i! #!#*(i%. C%! /&$i&6+# (# #*(i%. E(&(4 #9%4 #*&(% "i/i+4 %"-&"i!4 $#i(#!"i&4

'$&(% (# #"%+&$i(&(4 8&"*%$# (# $i#'%4 #!8#$)#(&(# (#*#"*&(&. U*i+i&!(% "%)%i!*$)#!*% (# $#"%+#""i! (# (&*%. U!& #!"#*& -&$& +& $#"%+#""i! (# (&*% #*i+i +& #!"#*& )#(i&!*# ! "#*i%!&$i% )#(i&!*# (% *i-% (# -$#'!*&(i"%*)i"& (# $#-#*& &6i#$*&.

2 CARACTERISTICAS SOCIODEMOGRAFICAS DE LA -ONA DE ESTUDIO

2.1. G$,graaE+ C&!*! (# O-%>#$i -#$*#!#"# & +& -$%/i!"i& C&$&!'&4 M!i"i-i% (#C%$># # #!"#!*$& & 120 ) (# +& "i(&( (# O$$%4 "%! !& #+#/&"i! (#3)..!.). &-$%9i)&(&)#!*# &+ $#*# (#+ D#-&$*&)#!*% #! #+ *$"*%

(#+ "&)i!% I!*#$!&"i%!&+ O$$%KPii'&.F# 8!(&(& )#(i&!*# L# (#+ P%(#$ L#'i+&*i/% #+ 1 (# %"*6$# (# 1?0($&!*# #+ #'!(% -#$i%(% (#+ -$#i(#!*# D$. V"*%$ P& E*#!%$%4 -%$"%!i'i#!*# # ++#/ #+ &"*% (# i!&'$&"i! "$#&"i! (#+ C&!*! (#O-%>#$i (# +& P$%/i!"i& C&$&!'& #! 8#",& 22 (# Di"i#)6$# (# 1?0.

L)($'

L% +)i*# (# +& P$%/i!"i& C&$&!'& %!:

1%


20/35

Li)i*& &+ #*# "%! +& P$%/i!"i& C#$"&(% ;T%+#(%= Li)i*& &+ N%$*# "%! +& P$%/i!"i& N%$ C&$&!'& H&++&)&$"&= Li)i*& &+ ( "%! +& P$%/i!"i& S( C&$&!'& ;A!(&)&$"&= Li)i*& &+ %#*# "%! +& P$%/i!"i& Li*%$&+ ;H&",&"&++&=

L% +)i*# (#+ C&!*! O-%>#$i %!:

Li)i*& &+ !%$*# "%! S&! A!*%!i% T$"% Li)i*& &+ O#*# "%! H&",&"&++& Li)i*& &+ S$ "%! +& P$&(#$& (# S&!


21/35

"&!*% & I!8#""i%!# R#-i$&*%$i& &'(& *i#!# !& &+*& i!"i(#!"i& ># # $#-%$*&!#)&!&+)#!*# (# 10 & 15 "&% #!*$# !i% &(+*% -#$% ># i#)-$# # /&"%!*$%+&!(%.

9.2. Sa%*& Ma($rna@ (a'a g%,a% &$ $"*n&&a&@ &$ ),r(a%&a& )a($rnanan(%

E! "&!*% & &+( )&*#$!& # )&!*i#!# !& &+( &"#-*&6+# -%$ +& )i)& -%6$#&(# +& '#!*# (i8i"+*&(4 ># *i#!#! +& )&($# #! &6&*#"#$# (# "%)#*i6+#. L&T&& '+%6&+ (# 8#"!(i(&( # &+*% (#6i(% & ># +& )&%$& (# +& )#$# #)-i#&! /i(& #9&+ & ) *#)-$&!& #(&( i! % (# )7*%(% &!*i"%!"#-*i/% -%$ *&+$&! "&i *%(& !#*$& #)6&$&&(& %! )#!%$# (# 25 &% "%! )&%$-$#/&+#!"i& #!*$# +% 15 20 &%.

9.9. P,%("a' &$ Sa%*&

E+ )i!i*#$i% *i#!# "%)% -%+*i"& (&$ &!*i"%!"#-*i/% (# )&!#$& '$&*i*& & )#$# #!#(&( 87$*i+.

3 PROTOCOLO DE INVESTIGACION

3.1. TITULO

FACTORES DE RIESGO MAS PREVALENTES PARA LAS ENFERMEDADES NOTRANSMISIBLES E INSIDENCIA DE LA /IPERTENSION ARTERIAL ARTRITISREUMATOIDE EN PERSONAS DE 25 A 65 AOS DE EDAD EN EL CANTON DEOPOQUERI DURANTE EL PRIMER TRIMESTRE DE LA GESTION 2015

3.2. DEFINICION DEL PROBLEMA

C+# %! +% 8&"*%$# (# $i#'% i(#!*i8i"&6+# -&$& +& #!8#$)#(&(# !%*$&!)ii6+# #! +& -%6+&"i! &(+*& (#+ "&!*! (# O-%>#$i ($&!*# #! #+ -$i)#$*$i)#*$# (# +& '#*i! 2015

3.9. ANTECEDENTES DEL PROBLEMA

L& /i(& )%(#$!& "%! $i*)% &"#+#$&(% #+#/&(% #!*i(% (# +& "%)-#*#!"i&4,&"# ># +& -#$%!& (#"i(#! -&+&*i!&)#!*# &+'!& $#& 8!(&)#!*&+#. P%$i'!%$&!"i&4 8&+*& (# *i#)-% % #*$7 &")+&(%4 )",& '#!*# & !% # "i(& #! ,6i*% &+i)#!*i"i% "%!)#! "%)i(& $-i(&4 "%!'#+&(& -&*#+#$& i!(*$i&+4"%*)6$# ># "%! #+ *i#)-% )#!%"&6& &+ #$ ,)&!%4 %6$#/i!i#!(% +& %6#i(&( !& #$i# (# "%)-+i"&"i%!# (# &+(.

L% &!*#$i%$ # %+% ! ##)-+% (# ")% &"*&! )",& (# +& #!8#$)#(&(#"$!i"& !% *$&!)ii6+# ;ECNT=4 (i'&)% ># -%$ (#"i(%4 +& #!8#$)#(&(#"&(& /# # $#&8i$)&! '&!&! *#$$#!% "%!/i$*i7!(%# #! +& $#-%!&6+# (#+ )&%$-%$"#!* (# )%$*&+i(&( #! +& -%6+&"i!.

21


22/35

Si! #)6&$'%4 #9i*# +& -%i6i+i(&( (# &*#!&$ +% #8#"*% (# +& #!8#$)#(&( %-$#/#!i$+& "%! +& i)-+# i!"+i! (# ,6i*% &+(&6+# & +& $*i!& (i&$i&. T#!i#!(%#! "#!*& +% "i*&(%4 # -#(# (#"i$ ># +& ECNT %! #!8#$)#(&(# ># # -#(#!-$#/#!i$. E -%$ #% ># +% '%6i#$!% #! '#!#$&+ +& i!*i*"i%!# (# &+( #!

-&$*i"+&$ # -$#%"-&! -%$ %8$#"#$ -$%'$&)& ># "%+&6%$#! "%! #*& i!*#!"i!(#6i(% & ># &+# ) "%*%% #+ *$&*&)i#!*% (# +& ECNT ># -$#/#!"i!.

L& #!8#$)#(&(# !% *$&!)ii6+# ;ENT= )&*&! & 3 )i++%!# (# -#$%!&"&(& &%.

C&i #+ 5 (# +& (#8!"i%!# -%$ ENT K2 )i++%!#K # -$%("#! #! +%- (# i!'$#% 6&% )#(i%.

1 )i++%!# (# +& )#$*# &*$i6i(& & +& #!8#$)#(&(# !% *$&!)ii6+# #-$%("#! #! -#$%!& )#!%$# (# 0 &% (# #(&( #+ 2 (# #*& )#$*#-$#)&*$&W %"$$#! #! - (# i!'$#% 6&% )#(i&!%.

L& #!8#$)#(&(# "&$(i%/&"+&$# "%!*i*#! +& )&%$& (# +& (#8!"i%!#-%$ ENT4 145 )i++%!# "&(& &%4 #'i(& (#+ "!"#$ ;42 )i++%!#=4 +!8#$)#(&(# $#-i$&*%$i& ;@ )i++%!#=4 +& (i&6#*# ;145 )i++%!#1=.

E*% "&*$% '$-% (# #!8#$)#(&(# %! $#-%!&6+# (# &+$#(#(%$ (#+ 2(# +& )#$*# -%$ ENT.

E+ "%!)% (# *&6&"%4 +& i!&"*i/i(&( 8i"&4 #+ % !%"i/% (#+ &+"%,%+ +&(i#*& )&+&!& &)#!*&! #+ $i#'% (# )%$i$ & "&& (# !& (# +& ENT

D#6i(% &+ &)#!*% (# +& )%$6i)%$*&+i(&( & "&& (# +& #!8#$)#(&(# !%*$&!)ii6+# #! #+ )!(%4 & "%)% *&)6i7! #! A)7$i"& L&*i!&.

3.3. JUSTIFICACION

E! !#*$% -& +& )%$6i)%$*&+i(&( -%$ +& #!8#$)#(&(# !% *$&!)ii6+# /&!&)#!*&!(% (& & (&4 #! !#*$% )#(i% #+ %""i(#!*# B%+i/i&!% +& #!8#$)#(&(#$#)*i"& "&$(i%/&"+&$# /&! &)#!*&!(% #! i!"i(#!"i&4 -&$& +% "&+ # $#&+i+ -$##!*# *$&6&%4 #! (%!(# # 6"&$& +% 8&"*%$# (# $i#'% ># !% ++#/&! &&(>i$i$ (i",& #!8#$)#(&(# "$!i"&.

3.5. MARCO TEORICO

DEFINICIN

L& #!8#$)#(&(# "$!i"& !% *$&!)ii6+# %! #!8#$)#(&(# (# "$%-$%+%!'&!(% ># !#"#i*&! *$&*&)i#!*% "%!*i!% -&$& "%!*$%+. N% # $##+/#!#-%!*!#&)#!*# $&$& /# # +%'$& !& "$& "%)-+#*&.

22


23/35

CLASIFICACION: L& OMS4 #+ P+&! N&"i%!&+ (# S&+( P6+i"& ;200K2010= &+'!&i!*i*"i%!# )7(i"& -$##!*&! "%)% ECNT & +& i'i#!*# #!8#$)#(&(#:

O$'&a&@E! C%+%)6i& +& L# 1355 (# 200? (#8i!# +& %6#i(&( +& #!8#$)#(&(#"$!i"& !% *$&!)ii6+# &%"i&(& & #*& "%)% !& -$i%$i(&( (# &+( -6+i"& #&(%-*&! )#(i(& -&$& "%!*$%+4 &*#!"i! -$#/#!"i!. E+ %6$#-#% +& %6#i(&(# (#8i!#! "%)% !& &")+&"i! &!%$)&+ % #9"#i/& (# '$&& ># -#(# #$-#$(i"i&+ -&$& +& &+(.

E+ !(i"# (# )&& "%$-%$&+ ;IMC= # ! i!(i"&(%$ i)-+# (# +& $#+&"i! #!*$# #+ -#% +& *&++& ># # *i+i& 8$#"#!*#)#!*# -&$& i(#!*i8i"&$ #+ %6$#-#% +& %6#i(&( #!+% &(+*%. S# "&+"+& (i/i(i#!(% #+ -#% (# !& -#$%!& #! i+% -%$ #+ "&($&(% (# *&++& #! )#*$% ;'X)2=. S#'! +& OMS4 ! IMC i'&+ % -#$i%$ & 25 (#*#$)i!&%6$#-#%. U! IMC i'&+ % -#$i%$ & 30 (#*#$)i!& %6#i(&(. E+ IMC -$%-%$"i%!& +&)#(i(& ) *i+ (#+ %6$#-#% +& %6#i(&( #! +& -%6+&"i!4 -#*% ># # +& )i)&-&$& &)6% #9% -&$& +% &(+*% (# *%(& +& #(&(#. Si! #)6&$'%4 ,& >#

"%!i(#$&$+& & **+% i!(i"&*i/% -%$># # -%i6+# ># !% # "%$$#-%!(& "%! #+)i)% !i/#+ (# '$%%$ #! (i8#$#!*# -#$%!&.

En$r)$&a&$' "ar&,a'"*%ar$' ECV@ # (#"i$4 (#+ "%$&! (# +% /&%&!'!#%4 %!: La cardiopata coronaria4 #!8#$)#(&( (# +% /&% &!'!#%># i$$i'&! #+ )"+% "&$(i&"% ;)i%"&$(i%=. Las enfermedades cerebrovasculares,#!8#$)#(&(# (# +% /&% &!'!#% ># i$$i'&! #+ "#$#6$%. Las arteriopatas

perifricas, #!8#$)#(&(# (# +% /&% &!'!#% ># i$$i'&! +% )i#)6$%-#$i%$# # i!8#$i%$#.

La cardiopata reumtica4 +#i%!# (#+ )i%"&$(i% (# +& /+/+& "&$(&"&

(#6i(& & +& 8i#6$# $#)*i"&4 !& #!8#$)#(&( "&&(& -%$ 6&"*#$i& (#!%)i!&(*$#-*%"%"%. Las cardiopatas congnitas4 )&+8%$)&"i%!# (#+ "%$&! -$##!*#(#(# #+ !&"i)i#!*%. Las trombosis venosas profundas y embolias pulmonares ,"%'+% (# &!'$# ;*$%)6%= #! +& /#!& (# +& -i#$!&4 ># -#(#! (#-$#!(#$#;7)6%+%= &+%&$# #! +% /&% (#+ "%$&! +% -+)%!#.

Los ataques al corazn y los accidentes vasculares cerebrales(AVC)#+#! #$8#!)#!% &'(% ># # (#6#! %6$# *%(% & %6*$""i%!# ># i)-i(#! ># +&&!'$# 8+& ,&"i& #+ "%$&! % #+ "#$#6$%. L& "&& ) 8$#"#!*# # +& 8%$)&"i!(# (#-i*% (# '$&& #! +& -&$#(# (# +% /&% &!'!#% ># i$$i'&! #+ "%$&!% #+ "#$#6$%. L% AVC *&)6i7! -#(#! (#6#$# & ,#)%$$&'i& (# +% /&%

"#$#6$&+# % "%'+% (# &!'$#.La hipertensin arterial (HT!# !& #!8#$)#(&( "&$&"*#$i&(& -%$ ! i!"$#)#!*%"%!*i!% (# +& "i8$& (# -$#i! &!'!#& #! +& &$*#$i&. A!># !% ,& ! )6$&+#*$i"*% ># -#$)i*& (#8i!i$ #+ +)i*# #!*$# #+ $i#'% +& #'$i(&(4 (# &"#$(% "%!"%!#!% i!*#$!&"i%!&+#4 !& -$#i! i*+i"& %*#!i(& -%$ #!"i)& (# 13? ))H'% !& -$#i! (i&*+i"& %*#!i(& )&%$ (# ? ))H'4 #*! &%"i&(& "%! !

23


24/35

&)#!*% )#(i6+# (#+ $i#'% (# &*#$%"+#$%i -%$ +% *&!*%4 # "%!i(#$& "%)% !&,i-#$*#!i! "+!i"&)#!*# i'!i8i"&*i/&.

Da$($': E !& #!8#$)#(&( #! +& ># +% !i/#+# (# '+"%& ;&"&$= (# +& &!'$##*! ) &+*%. L& '+"%& -$%/i#!# (# +% &+i)#!*% ># # "%!)#!. L& i!+i! !& ,%$)%!& ># &(& & ># +& '+"%& #!*$# & +& "7++& -&$& )i!i*$&$+##!#$'&. E! +& diabetes tipo uno4 #+ "#$-% !% -$%("# i!+i!&. E! +& diabetes tipodos4 #+ *i-% ) "%)!4 #+ "#$-% !% -$%("# % !% & +& i!+i!& &(#"&(&)#!*#.Si! 8i"i#!*# i!+i!&4 +& '+"%& -#$)&!#"# #! +& &!'$#.

C%! #+ *i#)-%4 #+ #9"#% (# '+"%& #! +& &!'$# -#(# "&&$ -$%6+#)& #$i%.P#(# -$%/%"&$ +#i%!# #! +% %%4 +% $i%!# +% !#$/i%. L& (i&6#*# *&)6i7!-#(# "&&$ #!8#$)#(&(# "&$(&"&4 (#$$&)# "#$#6$&+# # i!"+% +& !#"#i(&((# &)-*&$ ! )i#)6$%. L& )#$# #)6&$&&(& *&)6i7! -#(#! (#&$$%++&$(i&6#*#4 +& ++&)&(& (i&6#*# '#*&"i%!&+.

U! &!+ii (# &!'$# -#(# )%*$&$ i *i#!# (i&6#*#. E+ ##$"i"i%4 #+ "%!*$%+ (# -#% $#-#*&$ #+ -+&! (# "%)i(& -#(# &(&$ & "%!*$%+&$ +& (i&6#*#. T&)6i7! (#6#"%!*$%+&$ #+ !i/#+ (# '+"%& 4 i *i#!# $#"#*& )7(i"&4 *%)&$ )#(i"&)#!*%.

Ar(r(':E +& i!8+&)&"i! (# !& % ) &$*i"+&"i%!#. U!& &$*i"+&"i! # #+ $#&(%!(# (% ,#% # #!"#!*$&!. E9i*#! ) (# 100 *i-% (i8#$#!*# (# &$*$i*i. L&&$*$i*i i!/%+"$& +& (#'$&(&"i! (#+ "&$*+&'%4 #+ "&+ !%$)&+)#!*# -$%*#'# !&&$*i"+&"i!4 -#$)i*i#!(% ># 7*& # )#/& (# 8%$)& &/#. E+ "&$*+&'% *&)6i7!&6%$6# #+ '%+-# "&!(% # ##$"# -$#i! %6$# +& &$*i"+&"i!4 "%)% "#(#"&!(% !% "&)i!&. Si! +& "&!*i(&( &+ (# "&$*+&'%4 +% ,#% # $%&!4"&&!(% (%+%$4 ,i!",&! ;i!8+&)&"i!= $i'i(#.

L& i!8+&)&"i! (# +& &$*i"+&"i! -#(# $#+*&$ (#: U!& enfermedadautoinmunitaria;#+ i*#)& i!)!i*&$i% (#+ "#$-% &*&"& -%$ #$$%$ &+ *#i(% &!%=."ractura sea. D#'&*# (#*#$i%$% '#!#$&+ (# +& &$*i"+&"i%!#. #nfeccin4'#!#$&+)#!*# -%$ 6&"*#$i& % /i$. L& &$*$i*i -#(# -$##!*&$# #! ,%)6$# )#$#. La osteoartritis# #+ *i-% ) "%)!. O*$% *i-% "%)!# (# &$*$i*i %!4#!*$# %*$%: $spondilitis anquilosante% rtritis gonoccica% &ota% rtritisreumatoidea 'uvenil;#! !i%=4 O*$& i!8#""i%!# 6&"*#$i&!& ;&$*$i*i 6&"*#$i&!& !%'%!%""i"&=4 rtritis psorisica4 rtritis reactiva ;!($%)# (# R#i*#$=4 rtritis

reumatoidea;#! &(+*%=4 E"+#$%(#$)i&4 Lupus eritematoso sistmico;LES=.

Cn"$r: C!"#$ # ! *7$)i!% ># # & -&$& #!8#$)#(&(# #! +& ># "7++&&!%$)&+# # (i/i(#! i! "%!*$%+ -#(#! i!/&(i$ %*$% *#i(%. L& "7++&"&!"#$%& -#(#! (i#)i!&$# & %*$& -&$*# (#+ "#$-% -%$ #+ i*#)& &!'!#% -%$ #+ i*#)& +i!8*i"%. E+ "!"#$ !% # %+% !& #!8#$)#(&( i!% )",!8#$)#(&(#. H& ) (# 100 (i8#$#!*# *i-% (# "!"#$. L& )&%$& (# +%"!"#$# *%)&! #+ !%)6$# (#+ $'&!% % (# +& "7++& #! (%!(# #)-i#&! -%$

24


25/35

##)-+%4 #+ "!"#$ ># #)-i#& #! #+ "%+%! # ++&)& cncer de colon #+ "!"#$ >##)-i#& #! +& "7++& 6&&+# (# +& -i#+ # ++&)& carcinoma de clulas basales.

L% *i-% (# "!"#$ # -#(#! &'$-&$ #! "&*#'%$& ) &)-+i&. L& "&*#'%$&-$i!"i-&+# (# "!"#$ %!: arcinoma)"!"#$ ># #)-i#& #! +& -i#+ % #! *#i(%># $#/i*#! % "6$#! +% $'&!% i!*#$!%. *arcoma: "!"#$ ># #)-i#& #! ,#%4#! "&$*+&'%4 '$&&4 )"+%4 /&% &!'!#% %*$% *#i(% "%!!*i/% % (# %*7!.Leucemia: "!"#$ ># #)-i#& #! #+ *#i(% #! #+ ># # 8%$)& +& &!'$#4 "%)% +&)7(+& #&4 "&& ># # -$%("&! '$&!(# "&!*i(&(# (# "7++& &!'!#&&!%$)&+# ># #!*$#! #! +& &!'$#. Linfoma y mieloma: "!"#$# ># #)-i#&!#! +& "7++& (#+ i*#)& i!)!i*&$i%. nceres del sistema nervioso central:"!"#$# ># #)-i#&! #! +% *#i(% (#+ "#$#6$% (# +& )7(+& #-i!&+.

En$r)$&a& +*%),nar "r#n"a ;EPOC=: E !& (# +& #!8#$)#(&(# )"%)!# (# +% -+)%!# ># "&& (i8i"+*&( -&$& $#-i$&$. H& (% 8%$)&-$i!"i-&+#: +ronquitis crnica4 ># i)-+i"& !& *% -$%+%!'&(& "%! )%"%.$nfisema@># i)-+i"& +& (#*$""i! (# +% -+)%!# "%! #+ *i#)-%. L& )&%$& (#

+& -#$%!& "%! EPOC *i#!#! !& "%)6i!&"i! (# &)6& &8#""i%!#. L& "&&-$i!"i-&+ (# +& #!8#$)#(&( -+)%!&$ %6*$"*i/& "$!i"& ;EPOC= # #+ *&6&>i)%.

En$r)$&a&$' n$*r,%#g"a' "r#n"a'4 %! +& ># i'!% !*%)& -#$i*#!($&!*# &%4 # $#&+*&! +& i'i#!*#: ,emencias ;A+,#i)#$4 D4 C#$-% (#L#4 D#)#!"i& V&"+&$4 D#)#!"i& F$%!*%K*#)-%$&+4 O*$& (#)#!"i&(#'#!#$&*i/& #"!(&$i&=4 ccidente erebrovascular ;ACV= ;I"*=4$sclerosis -.ltiple4 Trastornos del -ovimiento: E!8#$)#(&( (# P&$i!%!4P&$+ii S-$&!"+#&$ P$%'$#i/&4 E!8#$)#(&( (# H!*i!'*%!4 Di*%!&4 Gi++# (# +&T%$#**# 4 E-&*i"i(&(4 S#"#+& (# *$&)&*i)% "$&!#&+# % #-i!&+#4 C#8&+#& %*$& &+'i& 8&"i&+#4 E-i+#-i&4 /atologa 0euromuscular: Mi%-&*&4 N#$%-&*&4

ELA4 Mi&*#!i& G$&/i4 P%+i% S!($%)# -%*-%+i%4 /arlisis cerebral infantil4S#"#+& (# "i$'& "#$#6$&+ % )#(+&$4 D&% "#$#6$&+ 8%"&+4 D&% C#$#6$&+ Di8%4D%+%$ "$!i"%.

FACTORES DE RIESGO PARA LAS ENFERMEDADES NO TRANSMISIBLES

C,n'*), &$ (aa",: +% #*% 8#$%! "+&i8i"&(% #! "&*#'%$& 1. N!"&8)&(%$: !!"& ,& 8)&(% $#'+&$)#!*# 2. F)&(%$ (i&$i%: 8)& (i&$i&)#!*# #!8%$)& $#'+&$ #! +% +*i)% )## 3. F)&(%$ %"&i%!&+: 8)& $#'+&$)#!*# #!+% +*i)% )##4 -#$% !% *%(% +% (& @. F)&(%$ $#'+&$ % &"*&+: 8)&(%$#(i&$i% %"&i%!&+# 5. E9 8)&(%$: 8# 8)&(%$ $#'+&$ -#$% & !% 8)& !&(&.

C,n'*), &$ a%",H,%:# "&+"+ +& "&!*i(&( (# '$&)% (# #*&!%+ i!'#$i(% -%$ )#4)&!(% +& #>i/&+#!"i& (# *%(% +% *i-% (# &+"%,%+ "%!)i(% ;"#$/#&4 /i!% (#*i+&(%= -%$ "&(& i!(i/i(%. L#'% +& -#$%!& # "+&i8i"&$%! #'! +% "$i*#$i%(# F$&)i!',&)15 -&$& #+ "%!)% )#!&+ *%*&+ (# #*&!%+ #! '$&)%. L&"&*#'%$& %!: B#6#(%$ +#/#4 ,&*& @2? 'X#*&!%+X)# B#6#(%$ )%(#$&(%: (#(#@30 & 1.??? 'X#*&!%+X)# B#6#(%$ #9&'#$&(%: ) (# 2.??? 'X#*&!%+X)#.

2!
http://www.scielo.cl/scielo.php?pid=S0034-98871999000800017&script=sci_arttext#15http://www.scielo.cl/scielo.php?pid=S0034-98871999000800017&script=sci_arttext#15http://www.scielo.cl/scielo.php?pid=S0034-98871999000800017&script=sci_arttext#15


26/35

A"(&a& '"a:# *i+i #+ C#*i%!&$i% (# B"#1># "%!*#)-+& 3 -&$*#:&"*i/i(&( 8i"& #! #+ *$&6&%4 &"*i/i(&( (#-%$*i/& &"*i/i(&( 8i"& #! #+ *i#)-% +i6$#.S%6$# +& 6 (# "$i*#$i% #*&6+#"i(%4 # &'$-&! +& %"-&"i%!# -%$ #+ !i/#+ (#i!*#!i(&( (# &"*i/i(&( 8i"& ># 7*% i!/%+"$&!4 #! !i/#+# 6&%4 )#(i% &+*%. L%)i)% %"$$# -&$& +% (#-%$*# &"*i/i(&( 8i"& #! #+ *i#)-% +i6$#. P%*#$i%$)#!*#4

# )&! +% *$# "%)-%!#!*# # "&+"+& ! -!* '+%6&+ ># # &'$-& +#'%#! &"*i/i(&( 8i"& +#/#4 )%(#$&(& % i!*#!&.

O$'&a&:# #/&+ #+ #*&(% !*$i*i/% "%! #+ I!(i"# (# M&& C%$-%$&+ #+ "&+ #"&+"+& (i/i(i#!(% #+ P#% -%$ +& T&++& &+ "&($&(% ;IMC[ P#%XT&++&2=141. L%i!(i/i(% # (i/i(#! #!: E!8+&>#"i(% \20 N%$)&+ ]20 \25 S%6$#-#% ]25 \30 O6#% ]30.

Pr$'#n ar($ra%:# *i+i #+ "$i*#$i% (#+ Joint National Committee on Prevention forHigh Blood Pressure1?4 ># #*&6+#"# +)i*# (# 1@0 -&$& +& -$#i! i*+i"& ?0

-&$& +& -$#i! (i&*+i"&4 &(#) (#+ % (# ($%'&

20

.Da$($' M$%%(*':#+ "$i*#$i% (i&'!*i"% # 6& #! +& )#(i"i! (# +& '+i"#)i& (#&!% & +& (% ,%$& (#-7 (# i!'#$i$ 5 ' (# '+"%& %$+& #! %+"i!&"%&21422.

P$r% %+&",:+% "$i*#$i% (# $i#'% #*! (#8i!i(% -%$ #+ P$%'$&)& N&"i%!&+ (#E("&"i! (#+ C%+#*#$%+23#! USA. L% !i/#+# %!: C%+#*#$%+ T%*&+ ]200 )'4C%+#*#$%+ HDL^35 )' C%+#*#$%+ LDL ]10 )'

/IPOTESIS

D#6i(% & ># #+ "&!*! (# %-%>#$i # #!"#!*$& #! #+ %""i(#!*# (# !#*$% -&B%+i/i&4 +& #!8#$)#(&(# $#)*i"& "&$(i%/&"+&$#4 & "%)% *&)6i7! #+&+"%,%+i)% %! +& ># ) -$#/&+#"#!.

OBJETIVO GENERAL

I(#!*i8i"&$ +% 8&"*%$# (# $i#'% ) -$#/&+#!*# -&$& +& #!8#$)#(&(# !%*$&!)ii6+# #! -#$%!& (# /#i!*i"i!"% & ##!*& &% )&%$# & ##!*& &%#! #+ "&!*! (# O-%>#$i.

OBJETIVOS ESPECIFICOS

C%!%"#$ +& -%6+&"i! (# &(+*% )&%$# (#+ "&!*! (# %-%>#$i I(#!*i8i"&$ +% 8&"*%$# (# $i#'% -$#/&+#!*# -%$ '$-% #*&$#% D&$ "%!%"i)i#!*% &"#$"& (# ")% -$#/#!i$ +% 8&"*%$# (# $i#'% C%!%"#$ +& i!"i(#!"i& (# +& #!8#$)#(&(# !% *$&!)ii6+#

3.. METODOLOGIA

2"
http://www.scielo.cl/scielo.php?pid=S0034-98871999000800017&script=sci_arttext#16http://www.scielo.cl/scielo.php?pid=S0034-98871999000800017&script=sci_arttext#17http://www.scielo.cl/scielo.php?pid=S0034-98871999000800017&script=sci_arttext#17http://www.scielo.cl/scielo.php?pid=S0034-98871999000800017&script=sci_arttext#18http://www.scielo.cl/scielo.php?pid=S0034-98871999000800017&script=sci_arttext#19http://www.scielo.cl/scielo.php?pid=S0034-98871999000800017&script=sci_arttext#20http://www.scielo.cl/scielo.php?pid=S0034-98871999000800017&script=sci_arttext#21http://www.scielo.cl/scielo.php?pid=S0034-98871999000800017&script=sci_arttext#21http://www.scielo.cl/scielo.php?pid=S0034-98871999000800017&script=sci_arttext#22http://www.scielo.cl/scielo.php?pid=S0034-98871999000800017&script=sci_arttext#22http://www.scielo.cl/scielo.php?pid=S0034-98871999000800017&script=sci_arttext#23http://www.scielo.cl/scielo.php?pid=S0034-98871999000800017&script=sci_arttext#16http://www.scielo.cl/scielo.php?pid=S0034-98871999000800017&script=sci_arttext#17http://www.scielo.cl/scielo.php?pid=S0034-98871999000800017&script=sci_arttext#18http://www.scielo.cl/scielo.php?pid=S0034-98871999000800017&script=sci_arttext#19http://www.scielo.cl/scielo.php?pid=S0034-98871999000800017&script=sci_arttext#20http://www.scielo.cl/scielo.php?pid=S0034-98871999000800017&script=sci_arttext#21http://www.scielo.cl/scielo.php?pid=S0034-98871999000800017&script=sci_arttext#22http://www.scielo.cl/scielo.php?pid=S0034-98871999000800017&script=sci_arttext#23


27/35

3..1. TIPO DE ESTUDIO

S# $#&+i ! #*(i% %6#$/&"i%!&+4 (#"$i-*i/%4 *$&!/#$&+.

3..2. UNIDADES DE OBSERVACION

S# ,&"# ! #*(i% #! +& "%)!i(&( (# O-%>#$i *$&6&&!(% "%! *%(& +& -#$%!! #(&( &(+*&4 &(+*% )&%$ *&!*% ,%)6$# "%)% )#$#.

3..9. DEFINICION DEL UNIVERSO DE ESTUDIO

S# *%)& & 100 -#$%!& (# +& "%)!i(&( (# O-%>#$i (# #9% )&"+i!% 8#)#!i!% #! #(&( &(+*& &(+*% )&%$.

3..3. MUESTRA

100 -#$%!& (# +& "%)!i(&( (# O-%>#$i (# #9% )&"+i!% 8#)#!i!% #! #(&(&(+*& &(+*% )&%$. E"%'i#!(% +& )#*$& (# 8%$)& &+#&*%$i& i)-+#. Si!*#*i&(! -#$%!& ># &"(#! & +& "%!+*& )7(i"& #*$&*i8i"&(& & -#$%!& >#"%)-$#!(#! #!*$# +% 25 & 0 &% &)%$# & 0 &%.

3..5. CRITERIOS.

D# i!"+i!: 100 -#$%!& ># $#i(#! #! +& "%)!i(&( (# O-%>#$i (# #9%)&"+i!% 8#)#!i!% ># "%)-$#!(#! #!*$# +% 25 0 &% )&%$# & 0 &%

D# #9"+i!: A -#$%!& )#!%$# & 25 &% ># !% "%$$#-%!(&! & +& "%)!i(&((# O-%>#$i.

3..6. FUENTES DE INFORMACION

E!*$#/i*& (# 8%$)& (i$#"*& )#(i&!*# ! i!*$)#!*% (# $#"%+#""i! (# (&*% & +&-%6+&"i! #! #*(i%4 *%)& (# -$#i! &$*#$i&+4 *%)& (# '+i"#)i&4 -#%4 *&++&.

3..7. VARIABLES DE ESTUDIO.E(&(4 S#9%4 E*&(% "i/i+4 O"-&"i!4 $#i(#!"i&4'$&(% (# #"%+&$i(&(.

3..8. METODOS@ INSTRUMENTOS O FORMULARIOS DE RECOLLECION DE

DATOS.

S# *i+i !& #!"#*& -&$& +& $#"%+#""i! (# (&*% # *i+i +& #!"#*& )#(i&!*#! "#*i%!&$i% )#(i&!*# (% *i-% (# -$#'!*& (i"%*)i"& (# $#-#*& &6i#$*&48%!#!(%"%-i%4 *#!i)#*$%4 '+")#*$%4 6&+&!&4 *&++i)#*$%.

3... PROCESAMIENTO DE DATOS:

2#


28/35

PERSONAS ENCUESTADAS Y EVALUADAS POR SEO

GENERO N KMASCULINO 3@FEMENINO 2

PERSONAS ENCUESTADAS Y EVALUADAS POR EDAD

EDAD N K25 30 &% 1031 @0 &% 12@1 50 &% 51 & 50 &%

M&%$# & 0 &% 25

FACTORES DE RIESGO EVALUADOS

FACTORES DE RIESGO N KTABACO

ALCOHOLSOBREPESO

ALIMENTACION INADECUADAANTECEDENTES DE ENT.OTROS

ENFERMEDADES NO TRANSMISIBLES DETECTADOS

ENF. NO TRANSMISIBLES N KARTRITIS REUMATOIDEHIPERTENSION ARTERIALDIABETESOBESIDADCANCER

SITUACION ACTUAL DE LA POBLACION

SITUACION N KSIN NINGUNA ENTSIN FACTOR DE RIESGO PARA ENT

2$


29/35

CON ALGUNA ENTCON FACTOR DE RIESGO PARAENT

3..10. PRESENTACION DE DATOS:3..11. ETICA DE LA INVESTIGACION:

3..12. PRESUPUESTO

5. RESULTADOS

6. CONCLUCIONES RECOMENDACIONES:

7. RECOMENDACIONES.

8. REFERENCIAS BIBLIOGRAFICAS.1. Rivera JA, Barquera S, Gonzalez-Cossio T, Olaiz G, Sepulveda J. Nutrition transition inMei!o and in ot"er #atin A$eri!an !ountries. Nutr Rev %&&'()%*+ t %S1'/-S10+.

%. Gonzlez-ier 2, Guti3rrez-4el5ado C, Stevens G, Barraza-#lor3ns M, orras-Conde6 R,Carval"o N, et al.4e7ini!i8n de prioridades para las interven!iones de salud en el Siste$ade rote!!i8n So!ial en Salud de M3i!o. Salud u9li!a Me %&&+('/*supl :S;+-S0%.

;. Boden"ei$er T,


30/35

/. @eart rote!tion Stud6 Colla9orative Group. MRCFB@ @eart rote!tion Stud6 o7!"olesterol lo>erin5 >it" si$vastatin in %&0;) "i5"-ris individuals a rando$izedpla!e9o !ontrolled trial. #an!et %&&%(;)&+-%%.

1&. @eart Out!o$es revention 2valuation Stud6 :nvesti5ators. 277e!ts o7 ra$ipril on!ardiovas!ular and $i!rovas!ular out!o$es in people >it" dia9etes $ellitus results o7 t"e@O2 stud6 and M:CRO-@O2 su9stud6. #an!et %&&&(;00%0;-%0/.

11. A5uilar-Salinas CA, Olaiz G, Ealles E, Rios JM, Go$ez-erez J, et al. @i5" prevalen!eo7 lo> @4# !"olesterol !on!entrations and $ied "6perlipide$ia in a Mei!an nation >idesurve6. J #ip Res %&&1('%1%/?-1;&+.

1%. A5uilar-Salinas CA, Roas R, Go$ez-erez J, Ealles E, Rios-Torres JM, ran!o A, et al.@i5" prevalen!e o7 t"e $eta9oli! s6ndro$e in Mei!o. Ar!" Med Res %&&'(;0+)-?1.

1;. A5uilar-Salinas CA, Roas R, Go$ez-erez J, Gar!ia 2, Ealles E, Rios-Torres JM, et al.2arl6 onset t6pe % dia9etes in a Mei!an, population-9ased, nation->ide surve6. A$ J Med%&&%(11;0)/-0+'.

1'. Olaiz G, Roas R, Barquera S, S"a$a" T, A5uilar-Salinas C, Cravioto , et al. 2n!uestaNa!ional de Salud %&&&. #a salud de los adultos. Cuernava!a, Morelos :nstituto Na!ionalde Salud H9li!a, %&&;.

10. Oliz-ernndez G, Rivera-4o$$ar!o J, S"a$a"-#ev6 T, Roas R, Eillalpando-@ernndez S, @ernndez-Ivila M, et al. 2n!uesta Na!ional de Salud 6 Nutri!i8n %&&).Cuernava!a, Morelos :nstituto Na!ional de Salud H9li!a, %&&).

1). Roas R, A5uilar-Salinas CA, Go$ez-erez J, Ealles E, ran!o A, Olaiz G, et al.Appli!a9ilit6 o7 t"e National C"olesterol 2du!ation ro5ra$ ::: *NC2-::: Guidelines 7ortreat$ent o7 d6slipide$ia in a non-Cau!asian population a Mei!an Nation-ide surve6. 4ia9 Care%&&;%)%&%1-%&%).

1/. :nternational 4ia9etes ederation. 4ia9etes Atlas. %da ed. Bruselas, B3l5i!a:nternational 4ia9etes ederation, %&&;.

%&. Rull JA, A5uilar-Salinas CA, Roas R, Rios-Torres JM, Go$ez-erez J, Olaiz G.2pide$iolo56 o7 t6pe % dia9etes in Mei!o. Ar!" Med Res %&&0(;)1??-1/).

3&


31/35

%1. T"e C4C 4ia9etes Cost-e77e!tiveness Group. Cost-e77e!tiveness o7 intensive 5l6!e$i!!ontrol, intensi7ied "6pertension !ontrol, and seru$ !"olesterol redu!tion 7or t6pe %dia9etes. JAMA %&&%(%?+%0'%-%001.

%%. Sa6da" S, radin J, Co>ie C. oor !ontrol o7 ris 7a!tors 7or vas!ular disease a$on5adults >it" previousl6 dia5nosed dia9etes. JAMA %&&'(%/1;;0-;'%.

%;. Rosas-eralta M, #ara-2squeda A, astelin-@ernndez G, Eelzquez-Monro6 O,Martnez-Redin5 J, M3ndez-Ortiz A, et al. Re-en!uesta Na!ional de @ipertensi8n Arterial*R2NA@TA Consolida!i8n Mei!ana de los 7a!tores de ries5o !ardiovas!ular. Co"ortena!ional de se5ui$iento. Ar!" Cardiol Me %&&0(+0/)-111.

%'. let!"er B, Berra =, Ades , Braun #, Bure #, et al.Mana5in5 a9nor$al 9lood lipids. A!olla9orative approa!". Cir!ulation %&&0(11%;1?'-;%&/.

%0. :nternational 4ia9etes ederation. Clini!al Guidelines Tas or!e. Gua 5lo9al para ladia9etes tipo %. Bruselas, B3l5i!a :nternational 4ia9etes ederation, %&&).

%). Bar!elo A, Aedo C, Rapat"a S, Ro9les S. T"e !ost o7 dia9etes in #atin A$eri!a andt"e Cari99ean. Bull iler 44. 4ont i5nore t"e patients. 4ia9 Care %&&1(%'1?'&-1?'1

;%. ord 2S, Aani K, Cro7t J, Cri!"le6 J, #a9art"e 4, et al.2plainin5 t"e de!rease in KSdeat"s 7ro$ !oronar6 disease, 1/?&-%&&&. N 2n5l J Med %&&+(;0)%;??-%;/?.

;;. @arris S, Lin$an B. ri$ar6 prevention o7 t6pe % dia9etes in "i5"-ris populations.4ia9 Care %&&&(%;?+/-??1.

;'. Al9erti =GMM, Li$$et , S"a> J. :nternational 4ia9etes ederation a !onsensus ont6pe % dia9etes prevention. 4ia9et Med %&&+(%''01-');.

31


32/35

;0. A$eri!an 4ia9etes Asso!iation. Standards o7 $edi!al !are in dia9etes *ositionState$ent. 4ia9 Care %&&'(%+*Suppl 1S10-S;).

;). @a77ner SM, Stern M, @azuda @, Mit!"ell B4, atterson J=. Cardiovas!ular ris7a!tors in !on7ir$ed predia9eti! individuals does t"e !lo! 7or !oronar6 "eart diseasestart ti!in5 9e7ore t"e onset o7 !lini!al dia9etes JAMA 1//&(%);%?/;-%?/?.

;+. T"e tas 7or!e on dia9etes and !ardiovas!ular diseases o7 t"e 2uropean So!iet6 o7Cardiolo56 *2SC and o7 t"e 2uropean Asso!iation 7or t"e Stud6 o7 4ia9etes *2AS4.Guidelines on dia9etes, pre-dia9etes and !ardiovas!ular diseases ee!utive su$$ar6.2ur @eart J %&&+(%???-1;)

;?. A5uilar-Salinas CA, G8$ez-3rez J. #a de!lara!i8n de A!apul!o. Rev :nves Clin%&&)(0?+1-++.

;/. 4oa CM, Eiss!"er T#S, Renders CM, Seidell JC. T"e prevention o7 over>ei5"t ando9esit6 in !"ildren and adoles!ents a revie> o7 interventions and pro5ra$$es. O9es Rev

%&&)(+111-1;).

'&. innis" 4ia9etes Asso!iation. :$ple$entation o7 t"e t6pe % dia9etes prevention planin inland. inland innis" 4ia9etes Asso!iation, %&&).

'1. Australian Centre 7or 4ia9etes Strate5ies. National eviden!e 9ased 5uidelines 7or t"e$ana5e$ent o7 t6pe % dia9etes $ellitus pri$ar6 prevention, !ase dete!tion anddia5nosis. Australia National @ealt" and Medi!al Resear!" Coun!il, %&&1.

'%.


33/35

'+. Mensa" G, Good$an R, Laza S, Moulton A, =o!"er , 4ietz < et al.#a> as a tool 7orpreventin5 !"roni! diseases epandin5 t"e spe!tru$ o7 e77e!tive pu9li! "ealt" strate5ies.reventin5 C"roni! 4isease %&&'. Consultado unio ;, %&&+.

'?. 4ia9etes revention ro5ra$ Resear!" Group. Redu!tion in in!iden!e o7 t6pe %dia9etes >it" li7est6le intervention or $et7or$in. N 2n5l J Med %&&%(;');/;-

'&;. [ Links]

'/. Tuo$ile"to J, #indstro$ J, 2risson J. revention o7 t6pe % dia9etes $ellitus 96!"an5es in li7est6le a$on5 su9e!ts >it" i$paired 5lu!ose toleran!e. N 2n5l J Med%&&1(;''1;';-1;0&.

0&. a>al R, Mau$dar S, Jo"nson J, Earne6 J, M!Alister . A s6ste$ati! revie> o7 dru5t"erap6 to dela6 or prevent t6pe % dia9etes. 4ia9 Care %&&0(%?+;)-+''.

01. Bu!"anan T. Can >e prevent t6pe % dia9etes 4ia9etes %&&+(0)10&%-10&+.

0%.


34/35

0/. 3rez A, Barri5uete-Mel3ndez JA, Rivera T. reven!i8n de las altera!iones de la!ondu!ta ali$entaria en 5rupos espe!7i!os dia9etes $ellitus. Rev :9eroa$ si!ol%&&0(1;?'-?+

)&. @er$an it" i$paired 5lu!ose toleran!e. Ann :ntern Med %&&0(1'%;%;-;;%.

)1. 2dd6 4, S!"lessin5er #, =a"n R. Clini!al out!o$es and !ost-e77e!tiveness o7 strate5ies7or $ana5in5 people at "i5" ris 7or dia9etes. Ann :ntern Med %&&0(1';%01-%)'.

)%. Ra$a!"andran A, Sne"alat"a C, Qa$una A, Mar6 S, in5 L. Cost-e77e!tiveness o7 t"einterventions in pri$ar6 prevention o7 dia9etes a$on5 Asian :ndians. 4ia9 Care%&&+(;&%0'?-%00%.

);. Gaede , Eedel , #arsen N, Jensen G, arvin5 @, edersen O. Multi7a!torialintervention and !ardiovas!ular disease in patients >it" t6pe % dia9etes. N 2n5l J Med

%&&;(;'?;?;-;/;

)'. Gaziano TA, Opie #@, it" $utire5i$en indevelopin5 >orld a !ost-e7e!tiveness anal6sis. #an!et %&&)(;)?)+/-)?).

)0. Si$$ons 4, Kpo"n M, Ga$9le G4. Can $edi!ation pa!a5in5 i$prove 5l6!e$i!!ontrol and 9lood pressure in t6pe % dia9etes 4ia9 Care %&&&(%;10;-10).

)). Nat"an 4, 4avidson M, 4eronzo R, @eine R, @enr6 R, ratle6 R, et al. :$paired7astin5 5lu!ose and i$paired 5lu!ose toleran!e. :$pli!ations 7or !are. 4ia9 Care%&&+(;&+0;-+0+.

C$(%/&KVi++&+%6%


35/35

Trabajo de Investigacionqqq

Documents

Transcript of Trabajo de Investigacionqqq